Skip to Content
MilliporeSigma
  • Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats.

Influence of combined therapy with rosuvastatin and amitriptyline on the oxidation-reduction status in rats.

Acta poloniae pharmaceutica (2013-10-24)
Mariola Herbet, Monika Gawrońska-Grzywacz, Anna Graca, Ewa Jagiełło-Wójtowicz
ABSTRACT

The aim of the present study was to assess the impact of combined therapy with rosuvastatin (10 mg/kg) and amitriptyline (10 mg/kg) on oxidation-reduction status in the blood of rats. After 2-week application of drugs alone or their combination, the activity of glutathione peroxidase (GPX), glutathione reductase (GR) and total antioxidant status (TAS) were determined. It was noticed that combined therapy with rosuvastatin and amitriptyline significantly increased the activity of GPX in comparison to the group receiving only rosuvastatin and decreased the activity of GR in comparison to groups receiving only rosuvastatin or amitriptyline. However, the activity of these enzymes as a result of combined therapy was placed in the level of the control groups. Our studies indicated that the combined therapy with both drugs caused an increase of TAS compared to the groups of animals receiving only one of these drugs. The results indicate on the oxidation-reduction balance and increasing the antioxidant status in rats treated with rosuvastatin and amitriptyline.

MATERIALS
Product Number
Brand
Product Description

USP
Amitriptyline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Amitriptyline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Amitriptyline hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Amitriptyline hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Glutathione Reductase human, buffered aqueous solution, ≥10 units/mg protein, recombinant, expressed in E. coli
Sigma-Aldrich
Amitriptyline hydrochloride, ≥98% (TLC), powder